skills/tooluniverse-drug-mechanism-research/SKILL.md
Trace drug mechanism of action — primary target → downstream signaling → pathway perturbation → tissue/organ effect → clinical outcome. Uses DrugBank, ChEMBL, KEGG, Reactome, STRING. Use for understanding how a drug works, identifying off-target effects, mechanism-based combination therapy design, and writing mechanism sections of reports.
npx skillsauth add mims-harvard/tooluniverse tooluniverse-drug-mechanism-researchInstall this skill globally with one command. Works with Claude Code, Cursor, and Windsurf.
3 of 9 scanners reported clean
Some scanners were skipped, did not run, or reported a non-clean status. Review each row below.
Drug mechanism research follows one core question chain:
Target -> Downstream Effect -> Pathway -> Organ Effect -> Clinical Outcome
Start with the drug's primary target. What receptor, enzyme, or transporter does it bind? Then trace forward: what does inhibiting/activating that target do immediately? What pathway is disrupted? What organ-level change results? What does the patient experience?
The LLM already knows drug pharmacology. This skill teaches HOW TO INVESTIGATE using available tools, not what mechanisms exist.
tooluniverse-adverse-event-detectiontooluniverse-drug-repurposingtooluniverse-drug-target-validationtooluniverse-network-pharmacologytooluniverse-pharmacogenomicsBefore investigating mechanism, resolve the drug name to a canonical identifier. You need a ChEMBL ID for most downstream queries.
# Resolve drug name to ChEMBL ID
result = tu.tools.OpenTargets_get_drug_id_description_by_name(drugName="metformin")
# Alternative: OpenTargets_get_drug_chembId_by_generic_name(drugName="metformin")
# Get PharmGKB ID (needed for PGx queries)
result = tu.tools.PharmGKB_search_drugs(query="metformin")
Fallback: If OpenTargets returns no hits, try PharmGKB_search_drugs or ChEMBL_get_drug with a known ChEMBL ID.
The first question: what does this drug bind to, and what does it do to that target?
Two complementary sources give you this:
# OpenTargets: quick summary of MOA with target gene symbols
moa = tu.tools.OpenTargets_get_drug_mechanisms_of_action_by_chemblId(chemblId="CHEMBL1431")
for row in moa["data"]["drug"]["mechanismsOfAction"]["rows"]:
print(f"{row['mechanismOfAction']} ({row['actionType']}) -> {row['targetName']}")
for t in row.get("targets", []):
print(f" Target gene: {t['approvedSymbol']} ({t['id']})")
# ChEMBL: detailed MOA with literature references and direct_interaction flag
mechs = tu.tools.ChEMBL_get_drug_mechanisms(drug_chembl_id__exact="CHEMBL1431")
for m in mechs["data"]["mechanisms"]:
print(f"MOA: {m['mechanism_of_action']}, Direct: {m['direct_interaction']}")
print(f" Refs: {[r['ref_id'] for r in m.get('mechanism_refs', [])]}")
Key fields to extract: action_type (INHIBITOR, AGONIST, ANTAGONIST, etc.), target gene symbol, direct_interaction (boolean), and literature references.
Known issue: OpenTargets_get_associated_targets_by_drug_chemblId may fail (GraphQL schema change). Extract targets from the MOA results instead.
Most drugs bind more than one target at clinical concentrations. After identifying the primary target, ask: what other proteins does this drug interact with? Off-target binding explains many side effects and drug interactions.
# ChEMBL bioactivity data shows binding affinity across targets
activities = tu.tools.ChEMBL_get_target_activities(target_chembl_id__exact="CHEMBL2364")
# STRING interaction partners reveal the target's protein network
partners = tu.tools.STRING_get_interaction_partners(identifiers="PRKAA1", species=9606)
Reasoning strategy: If ChEMBL MOA lists multiple targets, compare their action types. Same action type across related targets suggests on-pathway polypharmacology. Different action types suggest true off-target effects. The binding affinity (IC50/Ki from bioactivity data) tells you which targets matter at clinical doses -- nanomolar affinity is primary, micromolar is likely off-target.
A drug target does not work in isolation. Map it to its pathway to understand the breadth of effect.
Key question: Is the target upstream (affects many downstream genes, broader effects, more side effects) or downstream (narrow, specific effect)?
# KEGG: find gene ID, then get pathways
genes = tu.tools.kegg_find_genes(keyword="PRKAA1", organism="hsa")
pathways = tu.tools.KEGG_get_gene_pathways(gene_id="hsa:5562")
# Reactome: map protein to pathways (needs UniProt ID)
reactome = tu.tools.Reactome_map_uniprot_to_pathways(uniprot_id="Q13131")
# WikiPathways: search by gene symbol
wp = tu.tools.WikiPathways_find_pathways_by_gene(gene="PRKAA1")
# STRING: functional annotations (GO terms, pathway memberships)
annot = tu.tools.STRING_get_functional_annotations(identifiers="PRKAA1", species=9606)
For multi-target drugs, run pathway enrichment to find convergent pathways:
# Reactome enrichment (space-separated gene list, NOT array)
enrichment = tu.tools.ReactomeAnalysis_pathway_enrichment(identifiers="PRKAA1 PRKAA2 PRKAB1")
# STRING enrichment
enrichment = tu.tools.STRING_functional_enrichment(identifiers="PRKAA1 PRKAA2", species=9606)
Reasoning strategy: If multiple drug targets converge on the same pathway, that pathway is the drug's true mechanism. If targets are in different pathways, the drug has genuinely multi-pathway effects -- report each separately.
Drug labels describe WHAT the drug does. This is the FDA-approved mechanism narrative.
DailyMed requires a two-step process: search for the drug to get a setid, then parse specific label sections.
# Step 1: Get setid
spls = tu.tools.DailyMed_search_spls(drug_name="metformin")
setid = spls["data"][0]["setid"]
# Step 2: Parse the clinical pharmacology section (MOA, PK/PD, metabolism)
pharmacology = tu.tools.DailyMed_parse_clinical_pharmacology(
operation="parse_clinical_pharmacology", setid=setid)
# Drug interactions from the label
interactions = tu.tools.DailyMed_parse_drug_interactions(
operation="parse_drug_interactions", setid=setid)
# Contraindications
contra = tu.tools.DailyMed_parse_contraindications(
operation="parse_contraindications", setid=setid)
Other DailyMed parse tools: DailyMed_parse_adverse_reactions, DailyMed_parse_dosing.
Reasoning strategy: The label's clinical pharmacology section often describes the mechanism differently from database entries. The label emphasizes clinically relevant effects; databases emphasize molecular detail. Both perspectives are needed.
Pharmacogenomic variants affect how a patient responds to the drug. This matters for mechanism because PGx genes are often the drug's metabolizing enzymes or targets.
# CPIC gene-drug pairs (gold standard for PGx)
pairs = tu.tools.CPIC_search_gene_drug_pairs(gene_symbol="CYP2C19", cpiclevel="A", limit=20)
# Or search by drug
drug_info = tu.tools.CPIC_get_drug_info(name="clopidogrel")
# FDA PGx biomarkers (what's on the label)
fda_pgx = tu.tools.fda_pharmacogenomic_biomarkers(drug_name="clopidogrel", limit=100)
# Or find all drugs affected by a gene
fda_pgx = tu.tools.fda_pharmacogenomic_biomarkers(biomarker="CYP2D6", limit=100)
# PharmGKB gene details
gene_info = tu.tools.PharmGKB_search_genes(query="CYP2C19")
Reasoning strategy: CPIC Level A/B pairs have strong evidence and actionable guidelines. If a drug has CPIC Level A interactions, those genes are critical to its mechanism (usually metabolizing enzymes or direct targets). FDA PGx biomarkers tell you what's on the approved label.
Literature describes WHY the mechanism works. Combine with labels (what) for a complete picture.
# PubMed: returns a plain list of article dicts
articles = tu.tools.PubMed_search_articles(
query="metformin mechanism of action AMPK mitochondrial", limit=10)
# EuropePMC: returns {status, data, metadata}
articles = tu.tools.EuropePMC_search_articles(
query="metformin mechanism action mitochondrial", limit=10)
# Follow citation chains for seminal papers
citations = tu.tools.EuropePMC_get_citations(source="MED", identifier="12345678")
Search strategy: Start with "[drug] mechanism of action [primary target]". If the mechanism is debated, add the competing hypotheses as separate queries. Recent reviews (add "review" to query) give the current consensus.
## Drug Mechanism Report: [Drug Name]
### Drug Identity
- ChEMBL ID, PharmGKB ID, approval status
### Primary Mechanism
- Target: [gene symbol], Action: [INHIBITOR/AGONIST/etc.]
- Mechanism narrative (from DailyMed + databases)
- Direct interaction: yes/no
### Off-Target Effects
- Additional targets with action types and binding affinities
- Which off-targets explain known side effects
### Pathway Context
- Key pathways (from KEGG/Reactome/WikiPathways)
- Upstream vs downstream position of target
- Convergent pathways for multi-target drugs
### Pharmacogenomics
- CPIC gene-drug pairs with levels
- FDA PGx biomarkers
### Drug Interactions
- Mechanism-based interactions (enzyme inhibition/induction)
- Key interactions from DailyMed
### Evidence Summary
| Finding | Source | Tier |
|---------|--------|------|
| Primary MOA | ChEMBL + DailyMed | T1/T2 |
| Off-targets | ChEMBL bioactivity | T2 |
| Pathways | KEGG/Reactome | T3 |
| PGx | CPIC/FDA | T1 |
When comparing mechanisms, run Steps 2-4 for both drugs, then align:
for drug in [("metformin", "CHEMBL1431"), ("pioglitazone", "CHEMBL595")]:
moa = tu.tools.OpenTargets_get_drug_mechanisms_of_action_by_chemblId(chemblId=drug[1])
clin = tu.tools.DailyMed_parse_clinical_pharmacology(drug_name=drug[0])
| Step | Primary Tool | Fallback | |------|-------------|----------| | Drug ID | OpenTargets_get_drug_id_description_by_name | PharmGKB_search_drugs | | MOA | OpenTargets_get_drug_mechanisms_of_action_by_chemblId | ChEMBL_get_drug_mechanisms | | Pathways | KEGG_get_gene_pathways | WikiPathways_find_pathways_by_gene, Reactome_map_uniprot_to_pathways | | PGx | CPIC_search_gene_drug_pairs | fda_pharmacogenomic_biomarkers | | Clinical info | DailyMed_parse_clinical_pharmacology | OpenTargets_get_drug_description_by_chemblId | | DDI | DailyMed_parse_drug_interactions | PubMed_search_articles (DDI query) | | Literature | PubMed_search_articles | EuropePMC_search_articles |
MetaCyc note: MetaCyc requires a paid account and is not available. Use KEGG, Reactome, or WikiPathways instead.
tools
PCR / qPCR primer and oligo design — design forward/reverse primers for a target region (SantaLucia nearest-neighbor thermodynamics), compute melting temperature (Tm) and annealing temperature (Ta), check GC content, and screen an oligo for hairpins and primer-dimers. Use when you need primers for a sequence, want to QC an existing primer pair, or need the Tm of an oligo. Covers the primer-design rules (Tm matching, GC clamp, 3'-end, length) and the tools' constraint quirks.
tools
Pharmacokinetic (PK) analysis of concentration-time data — non-compartmental analysis (NCA) for Cmax, Tmax, AUC (0-t and 0-∞), terminal half-life, clearance (CL), volume of distribution (Vd), MRT, and absolute bioavailability (F). Also one-compartment fitting. Use when you have plasma/serum drug concentrations over time after a dose and need PK parameters, or to compute bioavailability from IV + oral AUCs. NOT for ADMET property prediction from structure (use tooluniverse-admet-prediction).
tools
Molecular cloning assembly design — Gibson Assembly (overlap design for seamless multi-fragment joining) and Golden Gate Assembly (Type IIS / BsaI / BbsI design with unique 4-bp fusion overhangs). Use when you need to plan how to join DNA fragments into a construct, design assembly overlaps/overhangs, or decide between cloning methods. Covers the domestication (internal-site removal), overhang-uniqueness, and overlap-Tm rules. For PCR primers to generate the fragments, see tooluniverse-primer-design.
tools
Meta-analysis / evidence synthesis — pool effect sizes across studies (odds ratios, risk ratios, hazard ratios, mean differences, correlations, GWAS betas) with fixed- or random-effects models, quantify heterogeneity (Q, I², τ²), and build a forest plot. Use when you have results from MULTIPLE studies and need a single pooled estimate, or to synthesize evidence from a systematic review / multiple GWAS / replicated experiments. Handles the error-prone effect-size + standard-error preparation (converting OR/HR/CI, two-group means±SD, proportions, and correlations into the (effect, SE) the pooling step needs).